tbuckley/cabot-search huggingface dataset:
The Lord Is My Shepherd
Authors: M Therese Southgate
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity
Authors: Toshimi Michigami, Nobuaki Shimizu, Paul J. Williams, Maria Niewolna, Sarah L. Dallas, Gregory R. Mundy, Toshiyuki Yoneda
Journal: Blood (2000)
Abstract 3764: Antibody therapy against granulin-epithelin precursor sensitizes liver cancer to chemotherapy
Authors: Nicholas Wong, Phyllis Cheung, Chi Wai Yip, Kui Fat Chan, Irene Ng, Sheung Tat Fan, Siu Tim Cheung
Journal: Cancer Research (2014)

Abstract The novel growth factor granulin-epithelin precursor (GEP, also named progranulin, acrogranin, or PC-derived growth factor) has shown to be upregulated in breast, ovary, prostate, liver and various human cancers. Our group has shown that GEP associated with chemo-resistance, recurrence and cancer stem cell properties in liver cancer [Gastroenterology 2011 and PLoS One 2011]. In the current study, we demonstrated that, both in vivo and in vitro, liver cancer cells that survived after chemotherapeutic agents demonstrated up-regulation of hepatic cancer stem cell marker CD133/GEP/ABCB5, and enhanced cancer stem cell properties, including colony formation and spheroid formation abilities. Importantly, combination of GEP antibody therapy and chemotherapy reversed the phenotypes induced by chemotherapy alone in the liver cancer cells and also the chemo-resistant subpopulations. Notably, combination of GEP antibody and cisplatin resulted in the eradication of all established intrahepatic human xenografts. This preclinical study demonstrated that combination treatment has the potential to be effective therapeutic regimen for GEP positive cancers. Citation Format: Nicholas Wong, Phyllis Cheung, Chi Wai Yip, Kui Fat Chan, Irene Ng, Sheung Tat Fan, Siu Tim Cheung. Antibody therapy against granulin-epithelin precursor sensitizes liver cancer to chemotherapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3764. doi:10.1158/1538-7445.AM2014-3764
Abstract 12677: Current Trend of Acute Myocardial Infarction in Korea: From Korea Acute Myocardial Infarction Registry Between 2006 and 2013
Authors: Myung Ho Jeong, Hyun Yi Kook, Youngkeun Ahn, Chong Jin Kim, Myeong Chan Cho, Young Jo Kim
Journal: Circulation (2014)

Background: Although the incidence of acute myocardial infarction (AMI) in Korea has been rapidly changed due to westernization of diet, life style and aging of the population, the recent trend of the myocardial infarction have not reported by classification. We investigated recent trends in the incidence and mortality associated with the 2 major types of acute myocardial infarction (AMI) Methods: We reviewed 36,525 patients registered in Korea Acute Myocardial Infarction Registry (KAMIR) for either ST-segment elevation acute myocardial infarction (STEMI) or non ST-segment elevation acute myocardial infarction (NSTEMI) between 2006 and 2012. Results: When the rate for AMI were investigated according to year, the incidence rates of STEMI declined markedly from 60.5% in 2006 to 49.7% in 2012 (p<0.001). In contrast to, a gradual increase in the incidence rates of NSTEMI was observed from 39.5% in 2006 to 50.3% in 2012 (p<0.001). As risk factors, diabetes mellitus (24.9%, 32.2% p<0.001), hypertension (46.7%, ...
THE BORDERLINE PSYCHOTIC PATIENT: THE IMPORTANCE OF DIAGNOSIS IN MEDICAL AND SURGICAL PRACTICE
Authors: M H MILLER
Journal: Annals of Internal Medicine (1957)

Article1 April 1957THE BORDERLINE PSYCHOTIC PATIENT: THE IMPORTANCE OF DIAGNOSIS IN MEDICAL AND SURGICAL PRACTICEMILTON H. MILLER, M.D.MILTON H. MILLER, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-46-4-736 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe great majority of patients who suffer from borderline psychotic illnesses are cared for by physicians in the general practice of medicine or in a nonpsychiatric specialty. The average physician will have many patients under his care who suffer from "mild psychoses," ambulatory schizophrenia, "pseudoneurotic schizophrenia" or severe paranoid illnesses. There are many patients with borderline psychotic illness—perhaps several million in this country. In addition, the percentage of such patients in an average practice is heightened because these marginally adjusted patients are often particularly concerned about their bodies. Their emotional illness finds expression through preoccupation with somatic complaints.Even with... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Madison, Wisconsin*Received for publication June 8, 1956.From the Department of Psychiatry, University Hospitals, Madison, Wisconsin.Requests for reprints should be addressed to Milton H. Miller, M.D., Department of Psychiatry, University Hospitals, 1300 University Avenue, Madison, Wisconsin. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDefining Borderline Patients: An OverviewReview of Consultation Psychiatry and Psychosomatic MedicineStaff Responses To Patients With a Primary Disturbance of the SelfIn the guise of organic diseaseThe diagnosis of pseudoneurotic schizophreniaAmbulatory schizophrenia 1 April 1957Volume 46, Issue 4Page: 736-743KeywordsEmotionsPatientsPrimary carePsychosesSchizophreniaThorax ePublished: 1 December 2008 Issue Published: 1 April 1957 PDF downloadLoading ...
Abstract 634: Combination chemotherapy significantly reduces indoleamine 2,3-dioxygenase activity in NSCLC patients
Authors: Cara C. Schafer, Yong Wang, Anandi Sawant, Tong Huan Jin, Selvarangan Ponnazhagan, Stefan C. Grant, Jessy S. Deshane
Journal: Cancer Research (2014)

Abstract Heterogeneity and immunosuppression in the tumor microenvironment (TME) has dampened the efficacy of current frontline combination chemotherapies for lung cancer which has provided limited improvement in patient survival. Modified amino acid metabolism in the TME contributes to lung cancer progression and suppression of anti-tumor immunity. Enhanced tryptophan metabolism in primary lung cancer patients is indicative of advanced disease stage. One of the key regulators of tryptophan metabolism is an intracellular, heme-containing enzyme indoleamine 2,3-dioxygenase (IDO). IDO catabolizes the breakdown of tryptophan into a toxic, immunosuppressive metabolite, L-Kynurenine (L-Kyn). Induction of IDO and accumulation of its metabolite correlates with poor prognosis and overall patient survival. We hypothesized that IDO enzymatic activity would be elevated in lung cancer patients compared to normal healthy controls. We predicted that combination chemotherapy strategies would modulate serum levels of L-Kyn and IDO activity in the immune compartment of lung cancer patients. Using an IDO enzymatic activity assay to measure the production of L-Kyn, we demonstrate that prior to receiving combination chemotherapies, Non-Small Cell Lung Cancer (NSCLC) patients (n=11) display significantly elevated levels of this immunosuppressive serum metabolite compared to healthy relatives (n=8) (Student's t-test p=0.000087; Paired Means p=0.0001). Following the second cycle of treatment, serum L-Kyn was reduced significantly (Student's t-test p=0.023; Paired Means p=0.043) in a subset of patients (n=3 of 5) suggesting response to chemotherapy, but these post-treatment levels remained elevated overall compared to healthy relatives. Additionally, greater levels of IDO enzymatic activity were observed in circulating immunosuppressive myeloid-derived suppressor cells from NSCLC patients and peripheral blood mononuclear cells prior to receiving combination chemotherapy compared to those from healthy relatives. These preliminary studies suggest that the IDO enzymatic pathway and tryptophan metabolism may serve as important therapeutic targets and diagnostic markers in predicting clinical outcomes of combination chemotherapies in the treatment of NSCLC in humans. Citation Format: Cara C. Schafer, Yong Wang, Anandi Sawant, Tong Huan Jin, Selvarangan Ponnazhagan, Stefan C. Grant, Jessy S. Deshane. Combination chemotherapy significantly reduces indoleamine 2,3-dioxygenase activity in NSCLC patients. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 634. doi:10.1158/1538-7445.AM2014-634
Abstract 9379: Higher Levels of Plasminogen-Activator Inhibitor 1 Are Associated with Progression of Coronary Artery Calcification in Middle-Aged Women: The Study of Women’s Health Across the Nation (SWAN) Heart Study
Authors: Norman C Wang, Karen A Matthews, Emma J Barinas-Mitchell, Chung-Chou H Chang, Samar R El Khoudary
Journal: Circulation (2014)

Introduction: Relationships of inflammatory and hemostatic biomarkers with progression of coronary artery calcification (CAC) in asymptomatic women are unknown. Hypothesis: We assessed the hypothesis that C-reactive protein (CRP), fibrinogen, plasminogen-activator inhibitor 1 (PAI-1), and tissue plasminogen activator antigen (tPA-ag) were associated with CAC progression in women free of known coronary heart disease (CHD) and stroke. Methods: CRP, fibrinogen, PAI-1, and tPA-ag were measured in SWAN Heart participants from the Pittsburgh and Chicago sites at baseline. CAC was obtained by CT scans and quantified by the Agatston score at baseline and after 2.3±0.5 years of follow-up. Significant CAC progression was defined as present if 1) CAC score was &gt;0 at follow-up in subjects with CAC score = 0 at baseline, 2) annualized change in CAC score was ≥10 in subjects with 0&lt;CAC score&lt;100 at baseline, and 3) annualized percent change in CAC score was ≥10% in subjects with CAC score ≥100 at baseline. Univariable and multivariable logistic regression were used for statistical analyses. The novel biomarkers were log-transformed. Baseline CAC was transformed as log(CAC+1). Results: The study included 252 women (32.5% black, 67.5% white; 56.4% pre- and early perimenopausal, 30.6% late peri- and postmenopausal, and 13.1% hormone therapy users) with a mean age of 51.2±2.6 years at baseline. In unadjusted analyses, log(PAI-1) and log(tPA-ag) were positively and significantly associated with CAC progression (p&lt;0.05), but log(CRP) and log(fibrinogen) were not. Adjusted analyses included the following covariates: baseline CAC, age, site, race, menopausal status, income, education, systolic blood pressure, body mass index, Homeostasis Model Assessment insulin resistance index, family history of cardiovascular (CV) disease, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, CV medication use, and current smoking. Only log(PAI-1) was significantly associated with CAC progression (OR: 1.91; 95% CI: 1.24-2.93; p=0.003). Conclusions: In conclusion, PAI-1 is associated with the presence of CAC progression in middle-aged women. Targeting PAI-1 may decrease atherogenesis beyond conventional CHD risk factors.
Pituitary-adrenal axis function in sickle cell anemia and its relationship to leukocyte alkaline phosphatase
Authors: Barry E. Rosenbloom, William D. Odell, Kouichi R. Tanaka
Journal: American Journal of Hematology (1980)

Abstract The function of the pituitary‐adrenal axis and leukocyte alkaline phosphatase activity were evaluated in eight patients with sickle cell disease during a painful crisis and when crisis‐free. The leukocyte alkaline phosphatase (LAP) score did not increase during crisis; the scores were in the low‐normal range during crisis and noncrisis periods. Insulin‐induced hypoglycemia produced normal growth hormone responses during both crisis and crisis‐free periods. Plasma cortisol concentrations were diminished in the crisis group. Also impaired was 11‐deoxycortisol production in both groups after metyrapone. These findings indicate that a mild defect in the hypothalamic‐pituitary‐adrenal axis exists in sickle cell disease patients.
A founder synonymous COL7A1 mutation in three Danish families with dominant dystrophic epidermolysis bullosa pruriginosa identifies exonic regulatory sequences required for exon 87 splicing
Authors: C. Covaciu, F. Grosso, E. Pisaneschi, G. Zambruno, P.A. Gregersen, M. Sommerlund, J.M. Hertz, D. Castiglia
Journal: British Journal of Dermatology (2011)

Dystrophic epidermolysis bullosa pruriginosa (DEB-Pr) (OMIM 604129) represents a distinct variant within the DEB clinical spectrum.1 It is characterized by intense pruritus and distinctive nodular prurigo-like and/or hypertrophic lichenoid lesions mainly localized on the arms, legs and upper shoulders.2 DEB-Pr is caused by either dominant (DDEB-Pr) or recessive mutations in the COL7A1 gene encoding type VII collagen (COLVII).3-5 The full spectrum of COL7A1 mutations in DEB-Pr remains elusive and the genotype–phenotype correlation is largely incomplete. Here, we report and functionally characterize a previously unrecognized translationally silent exonic COL7A1 mutation that results in skipping of exon 87 and is associated with DDEB-Pr phenotypes in several members of three apparently unrelated Danish families. A haplotype segregation study suggested a common ancestor in these kindred. Functional splicing analysis of the mutant exon by a COL7A1 minigene construct and computational prediction for splicing regulatory cis-sequences prove that the mutation alters the activity of an exonic splicing enhancer (ESE) critical for exon inclusion.6, 7 These findings substantiate for the first time the involvement of an ESE mutation in the pathogenesis of DEB and have implications for genetic counselling of Danish families with DDEB.
PEMPHIGUS NEONATORUM (BULLOUS CONTAGIOUS STAPHYLOCOCCIC IMPETIGO OF THE NEWLY BORN)..
Authors: F. DUDLEY HART
Journal: British Journal of Dermatology (1938)

Journal Article PEMPHIGUS NEONATORUM (BULLOUS CONTAGIOUS STAPHYLOCOCCIC IMPETIGO OF THE NEWLY BORN).: An Account of Two Epidemics and a Review of the Literature Get access F. DUDLEY HART, M.B. Edin., M.R.C.P. Lond F. DUDLEY HART, M.B. Edin., M.R.C.P. Lond Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 50, Issue 3, 1 March 1938, Pages 118–139, https://doi.org/10.1111/j.1365-2133.1938.tb10512.x Published: 01 March 1938
Abstract P215: Sleep Medication and Incident Stroke: The REGARDS Study
Authors: Megan E Petrov, Virginia J Howard, Dawn O Kleindorfer, Michael Grandner, Jennifer R Molano, George Howard
Journal: Circulation (2014)

Introduction: Preliminary evidence suggests sleep medications are associated with risk of vascular events; however, the long-term association with stroke risk is understudied. The aim of this study was to investigate the relation between sleep medication use and incident stroke. Methods: Within the REasons for Geographic And Racial Differences in Stroke study, 21,678 black and white participants (≥45 years) with no history of stroke were studied. Participants were recruited from 2003–2007. From 2008–2010, participants self-reported their prescription and over-the-counter sleep medication use over the past month. Suspected stroke events were identified on 6-month telephone contact, and associated medical records retrieved and physician adjudicated. Proportional hazards analysis was used to the estimate hazard ratios for incident stroke associated with sleeping medication use (0, 1–14, and 15+ days per month) controlling for sociodemographics, stroke risk factors, mental health symptoms, and sleep apnea risk. Results: At baseline, 9.6% of the sample used prescription sleep medication and 11.1% used over-the-counter sleep aids. Over an average follow-up of 3.3±1.0 years, 297 stroke events occurred. Over-the-counter sleeping medication use was associated (p = 0.014) with increased risk for incident stroke, with a 46% increased risk for use between 1 and 14 days a month (HR = 1.46; 95% CI: 0.99 - 2.15) and a 65% increased risk for use on 15 or more days (HR = 1.65; 95% CI: 0.96 - 2.85). There was no significant association with prescription sleep medications (p = 0.80). Discussion: Over-the-counter sleep medication use may independently increase the risk of stroke beyond other risk factors in middle-aged to older individuals with no history of stroke.
GP faces manslaughter charges
Authors: Clare Dyer
Journal: BMJ (1998)

A GP and three nurses are facing manslaughter charges over the death of an elderly patient in a nursing home who died two days after lapsing into a coma.

Jane Gustaffson, aged 46, who practises as a GP at Marlborough surgery, Seaham, County Durham, was formally charged with manslaughter at Peterlee police station last week, together with three nurses …
Combined Genotypes of CCR5, CCR2, SDF1, and HLA Genes Can Predict the Long-Term Nonprogressor Status in Human Immunodeficiency Virus-1–Infected Individuals
Authors: Magdalena Magierowska, Ioannis Theodorou, Patrice Debré, Françoise Sanson, Brigitte Autran, Yves Rivière, Dominique Charron, French ALT, IMMUNOCO Study Groups, Dominique Costagliola
Journal: Blood (1999)
Anticancer effects of novel gemcitabine-cardiolipin conjugates.
Authors: Pei-Yu Chien, Saifuddin Sheikh, Abdul R. Khan, Shoukath M. Ali, Moghis U. Ahmad, Imran Ahmad
Journal: Cancer Research (2006)

5418  Gemcitabine (2’,2’-difluorodeoxycytidine, dFdC or Gemzar®) is a nucleoside analogue used for the treatment of non-small cell lung and pancreatic cancer. After entering the cells through nucleoside transporters (NT), gemcitabine is phosphorylated and incorporated into DNA which leads to the termination of DNA elongation and cell death. The use of gemcitabine in clinic is limited because of dose-dependent toxicity, short half life due to rapid inactivation by deoxycytidine deaminase and most importantly, drug resistance. NT deficiency is one of the factors that contribute to gemcitabine resistance. We have previously shown that NEO6002, a conjugate of gemcitabine with ether analogue of C6 cardiolipin, can improve the efficacy and potentially overcome NT-deficient gemcitabine-resistant tumors (Chen et al., Anticancer Drugs 2005). To explore the possibility of developing a better cardiolipin-gemcitabine conjugate, we have synthesized several new conjugates where cardiolipin analogues were conjugated to gemcitabine via different linkers. The objective of the current study was to screen the biological activity of these new conjugates and compare with Gemzar® and NEO6002 in gemcitabine sensitive CCRF-CEM (human leukemia), A549 (human lung cancer), HT-29 (human colon cancer), and P388 (murine leukemia) cell lines. The compounds were also tested in gemcitabine-resistant cell lines, including ARAC-8C, A549GR-640, HT29GR-320, and P388GR-200. The cytotoxicity of these compounds was evaluated using sulforhodamine B (SRB) assay. Our results demonstrated that all the compounds tested were cytotoxic. Among these compounds, NEO6006 was particularly interesting because NEO6006 had a phosphate linker, different from the ester linker in NEO6002. Different hydrolysis mechanism may affect the bioavailability of conjugates inside the cells. When comparing the potency of NEO6006 with Gemzar in gemcitabine-resistant cell lines, NEO6006 induced strong cytotoxicity whereas no effect was observed with Gemzar® even at 500μM, the highest treatment level. In addition, A549GR-640 and HT29GR-320 cells had gained significantly less resistance to NEO6006 than to Gemzar®. Therefore, NEO6006 is an attractive therapeutic alternative for Gemzar®. Further experiments to evaluate the therapeutic efficacy of these gemcitabine-cardiolipin conjugates in animals are in progress.
Phenylketonuria in Yemenite Jews
Authors: B E COHEN, A SZEINBERG, H BOICHIS, E BODONYI
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bronchial Asthma: Principles of Diagnosis and Treatment.
Authors: M. Eric Gershwin
Journal: Annals of Internal Medicine (1986)

The contributors herein have carefully checked to ensure that the drug selections and dosages set forth in this text are accurate and in accord with the standards accepted at the time of publication.Notwithstanding, as new research, changes in government regulations, and knowledge from clinical experience relating to drug therapy and drug reactions constantly occurs, the reader is advised to check the product information provided by the manufacturer of each drug for any change in dosages or for additional warnings and contraindications.This is of utmost importance when the recommended drug herein is a new or infrequently used drug.It is the responsibility of the treating physician to determine dosages and treatment strategies for individual patients.Further it is the responsibility of the health care provider to ascertain the Food and Drug Administration status of each drug or device used in their clinical practice.The publisher, editors, and authors are not responsible for errors or omissions orfor any consequences from the application of the information presented in this book and make no warranty, express or implied, with respect to the contents in this publication.
Parental History and Myocardial Infarction Risk Across the World
Authors: Clara K. Chow, Shofiqul Islam, Leonelo Bautista, Zvonko Rumboldt, Afzal Yusufali, Changchun Xie, Sonia S. Anand, James C. Engert, Sumathy Rangarajan, Salim Yusuf
Journal: Journal of the American College of Cardiology (2011)